Dr. Mohammed Haseebuddin on Expanding Role for Immunotherapy in RCC
November 3rd 2016
Mohammed Haseebuddin, MD, a fellow in Urologic Oncology at Fox Chase Cancer Center, discuses why continued research into immunotherapy in clear cell renal cell carcinoma (RCC) is important, particularly in the adjuvant and neoadjuvant settings.